Cell Therapeutics Initiating Rolling NDA Submission For Pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that it began a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL). CTI expects to complete the submission this quarter and will request priority review which if granted could lead to an approval decision from the FDA in Q4 2009.

More: continued here

Filed under: Clinical Trials on April 15th, 2009